Cenduit to Launch Quantum Interactive™ Solution at DIA 2017
Cenduit LLC, a joint venture between QuintilesIMS and Thermo Fisher Scientific, is showcasing its solutions as an interactive response technology (IRT) specialist at DIA next week, June 19-21, in Chicago. Same Osman, Cenduit's new CEO, will present at the show, and the company will launch its newest study build software, Quantum Interactive™.
Quantum Interactive is technology-based and increases IRT quality by creating a functioning prototype of an initial study build within minutes, according to the company. It is a user-friendly interface that guides the study building process for faster requirements discovery and is highly configurable, regardless of study design.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
